Figure 1
![Figure 1](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2F1471-2407-13-242/MediaObjects/12885_2012_Article_3923_Fig1_HTML.jpg)
Disposition of patients in the study. *One patient was nonrandomly assigned to Arm A and received treatment with motesanib 125 mg QD. †Total shown does not reflect 2 additional patients who discontinued motesanib for other reasons but later were granted a waiver to continue in a rollover study.